{"id":"atomoxetine-or-placebo","safety":{"commonSideEffects":[{"rate":"~20%","effect":"Nausea"},{"rate":"~16%","effect":"Decreased appetite"},{"rate":"~9%","effect":"Insomnia"},{"rate":"~8%","effect":"Dizziness"},{"rate":"~7%","effect":"Fatigue"},{"rate":"~7%","effect":"Headache"},{"rate":"~6%","effect":"Mood swings"},{"rate":"~4%","effect":"Increased heart rate"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that blocks the norepinephrine transporter, preventing the reabsorption of norepinephrine from the synaptic cleft. This increases norepinephrine availability in the prefrontal cortex and other brain regions involved in attention and executive function. Unlike stimulant medications, it does not directly release norepinephrine or dopamine and has minimal abuse potential.","oneSentence":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in synapses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:47.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"},{"name":"ADHD in adolescents"}]},"trialDetails":[{"nctId":"NCT06573970","phase":"PHASE4","title":"Atomoxetine and Executive Function in PTSD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Posttraumatic Stress Disorder With Attention Defic","enrollment":160},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT04085172","phase":"PHASE4","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-09-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":396},{"nctId":"NCT04782830","phase":"NA","title":"Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-05","conditions":"Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure","enrollment":29},{"nctId":"NCT05293600","phase":"PHASE1, PHASE2","title":"Rescue Pharmacotherapy for OSA","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-01","conditions":"Obstructive Sleep Apnea","enrollment":70},{"nctId":"NCT04445688","phase":"PHASE2","title":"Crossover Trial of AD036 in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-07-15","conditions":"Obstructive Sleep Apnea","enrollment":62},{"nctId":"NCT02784535","phase":"PHASE2","title":"Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-08-29","conditions":"Neurogenic Orthostatic Hypotension","enrollment":48},{"nctId":"NCT04958460","phase":"PHASE3","title":"Effect of Probiotics on ADHD","status":"COMPLETED","sponsor":"Wang Liang-Jen","startDate":"2020-05-14","conditions":"ADHD, Probiotics, Gut Microbiota","enrollment":150},{"nctId":"NCT05071612","phase":"PHASE2","title":"Parallel Arm Trial of AD109 and AD504 In Patients With OSA","status":"COMPLETED","sponsor":"Apnimed","startDate":"2021-11-29","conditions":"OSA - Obstructive Sleep Apnea","enrollment":294},{"nctId":"NCT00716274","phase":"PHASE4","title":"Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Attention Deficit Hyperactivity Disorder, Dyslexia","enrollment":110},{"nctId":"NCT00176436","phase":"PHASE4","title":"Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-02","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT01522404","phase":"PHASE2","title":"Effects of Atomoxetine in Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Mild Cognitive Impairment","enrollment":39},{"nctId":"NCT02287038","phase":"PHASE4","title":"Atomoxetine in Veterans With Comorbid ADHD/PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-15","conditions":"Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder","enrollment":44},{"nctId":"NCT01019707","phase":"PHASE1","title":"Safety Assessment of Atomoxetine With MA IV Administration","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2009-10","conditions":"Methamphetamine Abuse, Methamphetamine Dependence","enrollment":6},{"nctId":"NCT00611533","phase":"NA","title":"Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2004-05","conditions":"Menopause, Cognitive Disturbances","enrollment":16},{"nctId":"NCT00417794","phase":"PHASE1","title":"Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2005-08","conditions":"Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)","enrollment":38},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":"Autonomic Failure, Orthostatic Hypotension","enrollment":389},{"nctId":"NCT02014064","phase":"PHASE1","title":"Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-08","conditions":"Continuous Methamphetamine Dependence, Methamphetamine Dependence in Remission","enrollment":41},{"nctId":"NCT00700427","phase":"PHASE3","title":"A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":2017},{"nctId":"NCT00548327","phase":"PHASE2","title":"The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype","status":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2007-10","conditions":"Schizophrenia, Memory Disorders, Cognition Disorders","enrollment":11},{"nctId":"NCT00216281","phase":"PHASE3","title":"Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia","status":"TERMINATED","sponsor":"Indiana University School of Medicine","startDate":"2005-09","conditions":"Schizophrenia","enrollment":126},{"nctId":"NCT00528697","phase":"PHASE2","title":"A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-09","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":278},{"nctId":"NCT01127646","phase":"PHASE4","title":"A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT00218322","phase":"PHASE4","title":"Effectiveness of ATMX in Treating Adolescents With ADHD and SUD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-09","conditions":"Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders","enrollment":108},{"nctId":"NCT00856063","phase":"PHASE4","title":"Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2009-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":5},{"nctId":"NCT01343628","phase":"PHASE1","title":"A Gene by Medication Interaction to the Acute Effects of Alcohol","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2008-01","conditions":"Alcohol-induced Cue-craving, Alcohol Sensitivity","enrollment":43},{"nctId":"NCT00607568","phase":"PHASE1, PHASE2","title":"Atomoxetine Effects in Humans","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-06","conditions":"Physiological Stress","enrollment":10},{"nctId":"NCT00190775","phase":"PHASE4","title":"A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":502},{"nctId":"NCT00429091","phase":"PHASE2","title":"A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-01","conditions":"Attention-Deficit/Hyperactivity Disorder, ADHD","enrollment":243},{"nctId":"NCT00566371","phase":"PHASE4","title":"The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2005-06","conditions":"Attention Deficit Hyperactivity Disorder, Insomnia","enrollment":36},{"nctId":"NCT00546910","phase":"PHASE4","title":"Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":125},{"nctId":"NCT00191906","phase":"PHASE4","title":"Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-04","conditions":"Attention Deficit Hyperactivity Disorder, Reading Disorder","enrollment":121},{"nctId":"NCT00192023","phase":"PHASE3","title":"An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-10","conditions":"Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder","enrollment":139},{"nctId":"NCT00191698","phase":"PHASE3","title":"Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-12","conditions":"Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder","enrollment":226},{"nctId":"NCT00174226","phase":"PHASE2","title":"Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":241},{"nctId":"NCT00486122","phase":"PHASE4","title":"Evaluation of Continuous Symptom Treatment of ADHD","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":282},{"nctId":"NCT00485550","phase":"PHASE3","title":"Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":14},{"nctId":"NCT00485862","phase":"PHASE4","title":"Combination Therapy in Patients With Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-06","conditions":"Depressive Symptoms","enrollment":214}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"atomoxetine (or placebo)","genericName":"atomoxetine (or placebo)","companyName":"University of Arizona","companyId":"university-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in synapses. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, ADHD in adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}